期刊文献+

LL-37在酒渣鼻发病机制中的研究进展 被引量:9

Research Advances of LL-37 in the Pathogenesis of Rosacea
下载PDF
导出
摘要 酒渣鼻是一种天然免疫反应增强的炎症性皮肤病。LL-37是皮肤中天然免疫的重要效应分子,具有诱导新生血管和促进炎症反应的作用。LL-37在酒渣鼻皮损中高表达,参与酒渣鼻红斑、毛细血管扩张和炎性丘疹的形成。日光、毛囊蠕形螨等外界环境刺激通过多种途径上调LL-37的活性及分泌。LL-37与酒渣鼻的发病机制密切相关,是一种有前途的酒渣鼻治疗靶点。 Rosacea is an inflammatory skin disease characterized by accentuation of innate immune response. LL-37 is an important effector molecules of innate immunity in the skin, which ean induce angiogenesis and promote inflammation. The high expression of LL-37 in the lesions of rosacea contributes to erythema, telangiectasias and inflammatory papules of the disease. The activity and secretion of LL-37 was upregulated by sunlight, de- modex folliculorum and other external environmental stimuli through a variety of ways. LL-37 has an intimate association with the pathogenesis of rosacea, and serve as a promising treatment target for rosacea.
作者 李婷 胡阳
出处 《中国皮肤性病学杂志》 CAS CSCD 北大核心 2015年第7期738-740,共3页 The Chinese Journal of Dermatovenereology
基金 上海市医学重点专科B类建设项目(ZK2012B18) 上海市卫生局科研课题(ZK2012B18)
关键词 酒渣鼻 天然免疫 LL-37 抗菌肽 Rosacea Innate immunity LL-37 Antimicrobial peptide
  • 相关文献

参考文献24

  • 1Del Rosso JQ. Advances in understanding and managing msacea: part 1 : connecting the dots between pathophysiological mecha- nisms and common clinical features of rosa- cea with emphasis on vascular changes and facial erythema [ J ]. J Clin Aesthet Derma- tol,2012,5(3) :16 -25.
  • 2Yamasaki K, Gallo RL. The molecular pa- thology of rosacea [J]. J Dermatol Sci, 2009,55(2) :77 -81.
  • 3蔡林,孙青苗.抗菌肽与皮肤疾病关系的研究进展[J].中国皮肤性病学杂志,2011,25(1):1-5. 被引量:11
  • 4Meyer-Hoffert U, Schroder JM. Epidermal proteases in the pathogenesis of rosaeea [ J ]. J Invest Dermato1,2011,15 ( 1 ) : 16 - 23.
  • 5Yamasaki K, Di Nardo A, Bardan A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in msacea [ J]. Nat Med, 2007,13 ( 8 ) : 975 - 980.
  • 6Casas C,Paul C,Lahfa M,et al. Quantification of Demodex folliculommby PCR in msacea and its relationship to skin innate immune activation [J]. Exp Dermatol, 2012, 21 (12) :906 -910.
  • 7Yamasaki K, Kanada K, Macleod DT, et al. TLR2 expression is increased in Rosa- cea and stimulates enhanced serine prete- ase production by keratinocytes [ J]. J In- vest Dermatol, 2011,131 ( 3 ) :688 - 697.
  • 8Antal AS, Dombrowski Y, Koglin S, et al. Impact of vita rain D3 on cutaneous im- munity and antimicrebial peptide expres- sion [J]. Dermatoendocrinol, 2011, 3 (1) :18 -22.
  • 9Park K, Elias PM, Oda Y, et al. Regulation of cathelicidin antimicrebial peptide expres- sion by an endoplasmic reticulum (ER) stress signaling, vitamin D receptor-inde- pendent pathway [J]. J Biol Ghem,2011, 286(39) :34121 -34130.
  • 10Aroni K,Tsagroni E, Kavantzas N. A study of the pathogenesis of Rosacea: how angio- genesis and mast cells may participate in a complex muhifactorial process [J]. Arch Dermatol Res,2008,300(3) :125 - 131.

二级参考文献36

  • 1Yamasaki K, Di Nardo A, Bardan A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea[J]. Nat Med, 2007, 13(8): 975-980.
  • 2Yamasaki K, Schauber J, Coda A, et al. Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin[J]. FASEB J, 2006, 20(12): 2068-2080.
  • 3Hachem JP, Houben E, Crumrine D, et al. Serine protease sig- naling of epidermal permeability barrier homeostasis[J]. J Invest Dermatol, 2006, 126(9): 2074-2086.
  • 4Wilkin J, Dahl M, Detmar M, et al. Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea[J]. J Am Acad Der- matol, 2004, 50 (6): 907-912.
  • 5Elias PM, Hatano Y, Williams ML. Basis for the barrier abnor- mality in atopic dermatitis: outside-inside-outside pathogenic mechanisms[J]. J Allergy Clin Immunol, 2008, 121(6): 1337- 1343.
  • 6Elias PM, Arbiser J, Brown BE, et al. Epidermal vascular en- dothelial growth factor production is required for permeability barrier homeostasis, dermal angiogenesis, and the development of epidermal hyperplasia: implications for the pathogenesis of psori- asis[J]. Am J Pathol, 2008, 173(3): 689-699.
  • 7Denda M, Kitamura K, Elias PM, et al. trans-4-(Aminomethyl) cyclohexane carboxylic acid (T-AMCHA), an anti-fibrinolytic a- gent, accelerates barrier recovery and prevents the epidermal hy- perplasia induced by epidermal injury in hairless mice and hu- mans[J]. J Invest Dermatol,1997, 109(1): 84-90.
  • 8Katsuta Y, Yoshida Y, Kawai E, et al. trans-4-(Aminomethyl)cy- clohexane carboxylic acid methylamide (t-AMCHA methylamide) inhibits the physical interaction between urokinase-type plas- minogen activator and stratum corneum, and accelerates the re- covery of barrier function[J]. J Dermatol Sci, 2005, 40(3): 218- 220.
  • 9Del RJ. Advances in understanding and managing rosacea: part 1: connecting the dots between pathophysiological mechanisms and common clinical features of rosacea with emphasis on vas- cular changes and facial erythema [J]. J Clin Aesthet Dermatol, 2012, 5(3): 16-25.
  • 10Choi KY, Chow LN, Mookherjee N. Cationic host defence pep- tides: muhifaceted role in immune modulation and inflammation [J]. J Innate Immun, 2012, 4(4): 361-370.

共引文献28

同被引文献67

  • 1Lehmann P. Rosacea: Clinical features and lassification[J]. Hautarzt,2013,64(7):489-493.
  • 2Tan J,Berg M. Rosacea:current state of epidemiology[J].J Am Acad Dermatol,2013,69(6):Suppl 1 :S27-S35.
  • 3Crawford G,Pelle M,James W, et al.Rosacea: Etiology,pathogenesis,and subtype classification[J].Am Acad Dermatol,2004,51(3):327-341.
  • 4Del Rosso JQ,Schlessinger J,Werschler P.Comparison of antiinflammatory dose doxycycline versus doxycycline 100mg in the treatment ofrosacea[J].J Drugs Dermatol,2008,7(6):573-576.
  • 5Maddin S.A comparison of topical azelaic acid 20% creamand topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea[J]. J Am Acad Dermatol, 1999,40(6):961-965.
  • 6Cribier B.Physiopathology of rosacea[J].Ann Dermatol Venereol,2014,141 (12): 158-164.
  • 7Anetta E,Diane B.The treatment of rosacea[J].Cosmetic Dermatol,2011,24 (8): 186-192.
  • 8Hongcharu W, Taylor CR,Chang Y, et al. Topical ALA- photodynamic therapy for the treatment of ache vulgaris[J].J Invest Dermatol,2000,115(2): 183-192.
  • 9Paller AS,Lebwoh M,Fleischer AB,et al.Tacrolimus ointment is more effective than pimecrolimu scream with a similar safety profile in the treatment of atopic dermatitis:Results from 3r and omized comparative studies[J].J Am Acad Dermatol,2005,52(5):810-822.
  • 10李雪莉,黄玉成,杨莉.他克莫司软膏治疗酒渣鼻临床疗效观察[J].中国皮肤性病学杂志,2009,23(6). 被引量:13

引证文献9

二级引证文献73

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部